# ENB Therapeutics

Source: https://onco.cc/companies/enb-therapeutics/  
OnCo record `enb-therapeutics` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

ENB Therapeutics is a New York biotech that blocks the endothelin B receptor, a switch tumours use to shut out immune cells, so that checkpoint inhibitors work in melanoma and other cancers that had stopped responding.

## Summary

ENB Therapeutics develops ENB-003, a selective endothelin B receptor antagonist. Endothelin B signalling in the tumour vasculature and on tumour cells blocks T-cell infiltration and supports immune evasion; ENB-003 is designed to reverse this. It has been tested with pembrolizumab in a phase 1/2 study in advanced melanoma, ovarian cancer and other solid tumours that had progressed on checkpoint inhibitors.

## Fields

- Kind: Company
- Last checked: 2026-09-17
- Also known as: ENB Therapeutics, Inc.
- Tags: drug-maker
- HQ: New York, New York
- Type: biotech

## Connected records

- drugs: [ENB003](https://onco.cc/drugs/enb003/)

---
JSON: https://onco.cc/api/v1/entities/enb-therapeutics.json